Pulmonology

Your Article Summary

See Latest Articles

A Pipeline of Therapies for Cystic Fibrosis
Seminars in Respiratory and Critical Care Medicine, 09/23/09

Ashlock MA et al. – The more than 30 compounds currently in the pipeline of Foundation–funded therapeutics are used as a platform to discuss why and how therapeutic strategies are brought into clinical development. Consideration is also given to the funding, management, and infrastructure necessary and practical to support the progression of drug candidates and the availability of therapeutics for use by individuals with CF. The importance of the clinical trial process and relevant outcome measures to assess the efficacy of drug candidates is also discussed. Finally, the potential impact of the pipeline for individuals with CF is summarized.

Related Articles

See all related articles

Vitamin D supplementation for cystic fibrosis
Cochrane Reviews, 10/28/09    Relevance Score: 69%

Genetic Risk Factor for Liver Disease for Patients With Cystic Fibrosis
Gastroenterology, 10/27/09    Relevance Score: 69%

Inspire Announces Presentation at the North American Cystic Fibrosis Conference and Provides Enrollment Update for Phase 3 Cystic Fibrosis Trial
Inspire, 10/16/09    Relevance Score: 69%

Pulmonary nocardiosis in cystic fibrosis
Journal of Cystic Fibrosis, 10/07/09    Relevance Score: 69%

Cystic fibrosis neutrophils have normal intrinsic reactive oxygen species generation
European Respiratory Journal, 10/23/09    Relevance Score: 68%

Today in Cystic Fibrosis...keeping you current

Receive free subspecialty "5-minute updates" via email

Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09

Modulation of endocytic trafficking and apical stability of CFTR in primary human airway epithelial cultures
Lung Cellular and Molecular Physiology, 12/16/09

Influenza Associated Cystic Fibrosis Pulmonary Exacerbations
Chest, 12/14/09

 See all of Cystic Fibrosis